Table 1 Quality assessment using the CHEERS 2022 statement checklist
Section/Item | FULL ECONOMIC EVALUATIONS | PARTIAL ECONOMIC EVALUATIONS | ||||||
|---|---|---|---|---|---|---|---|---|
Italy | United Kingdom | USA | United Kingdom | |||||
Cosimelli, 2013 [24] a | Bester, 2013 [23] a | Pennington, 2015 [25] b | Brennan, 2020 [26] b | Loveman, 2014 [27] b | Fusco, 2017 [28] a | Dhir, 2018 [29] b | ||
1 | Title | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
2 | Abstract | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
3 | Background and objectives | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
4 | Health economics analysis plan | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
5 | Study population | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
6 | Setting and location | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
7 | Comparators | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
8 | Perspective | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
9 | Time horizon | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
10 | Discount rate | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
11 | Selections of outcomes | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
12 | Measurement of outcomes | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
13 | Valuation of outcomes | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
14 | Measurement and valuation of resources and cost | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
15 | Currency, price date, and conversion | 0 | 1 | 0 | 1 | 1 | 1 | 0 |
16 | Rationale and description of model | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
17 | Analytic methods and assumptions | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
18 | Characterizing heterogeneity | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
19 | Characterizing distributional effects | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
20 | Characterizing uncertainty | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
21 | Approach to engagement with patients and others affected by the study | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
22 | Study parameters | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
23 | Summary of main results | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
24 | Effect to uncertainly | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
25 | Effect of engagement with patients and others affected by the study | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
26 | Study findings, limitations, generalizability, and current knowledge | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
27 | Source of funding | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
28 | Conflicts of interest | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
Total | 10 | 18 | 24 | 26 | 26 | 13 | 21 | |
% (n) | 36% | 64% | 86% | 93% | 93% | 52% | 84% | |